Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 3
1991 5
1992 6
1993 6
1994 14
1995 8
1996 28
1997 17
1998 17
1999 14
2000 11
2001 15
2002 11
2003 15
2004 8
2005 9
2006 15
2007 11
2008 7
2009 8
2010 15
2011 12
2012 10
2013 17
2014 22
2015 15
2016 15
2017 18
2018 14
2019 17
2020 17
2021 6
Text availability
Article attribute
Article type
Publication date

Search Results

377 results
Results by year
Filters applied: . Clear all
Page 1
Managing Scalp Psoriasis: An Evidence-Based Review.
Wang TS, Tsai TF. Wang TS, et al. Am J Clin Dermatol. 2017 Feb;18(1):17-43. doi: 10.1007/s40257-016-0222-4. Am J Clin Dermatol. 2017. PMID: 27650520 Review.
RESULTS: To our knowledge, few randomized controlled trials (RCTs) are conducted specifically in scalp psoriasis. Topical corticosteroids provide good effects and are usually recommended as first-line treatment. Calcipotriol-betamethasone dipropionate is well tolera …
RESULTS: To our knowledge, few randomized controlled trials (RCTs) are conducted specifically in scalp psoriasis. Topical corticosteroids pr …
A Review of Topical Corticosteroid Foams.
Payne J, Habet KA, Pona A, Feldman SR. Payne J, et al. J Drugs Dermatol. 2019 Aug 1;18(8):756-770. J Drugs Dermatol. 2019. PMID: 31424707 Review.
Furthermore, BMV foam cleared or almost cleared 72% of scalp psoriasis subjects compared with BMV lotion (P0.005%). For calcipotriol plus betamethasone dipropionate foam, 38.3% of psoriasis subjects achieved treatment success compared with placebo (22.5%; P<0.001). ...
Furthermore, BMV foam cleared or almost cleared 72% of scalp psoriasis subjects compared with BMV lotion (P0.005%). For calcipotriol
Field cancerization: Treatment.
Cornejo CM, Jambusaria-Pahlajani A, Willenbrink TJ, Schmults CD, Arron ST, Ruiz ES. Cornejo CM, et al. J Am Acad Dermatol. 2020 Sep;83(3):719-730. doi: 10.1016/j.jaad.2020.03.127. Epub 2020 May 6. J Am Acad Dermatol. 2020. PMID: 32387663 Review.
Other considerations include treatment efficacy, cost, side effects, and patient preference. Field therapies are preferred because they address clinically visible disease and subclinical atypia. ...
Other considerations include treatment efficacy, cost, side effects, and patient preference. Field therapies are preferred because th …
Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events.
Subedi S, Gong Y, Chen Y, Shi Y. Subedi S, et al. Drug Des Devel Ther. 2019 Jul 23;13:2491-2502. doi: 10.2147/DDDT.S200147. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31413544 Free PMC article. Review.
Infliximab, a murine-human monoclonal antibody, is highly efficacious in the treatment of moderate-to-severe psoriasis, with better skin clearance and faster onset of action than topical medications such as methotrexate, narrow-band ultraviolet B, and calcipotriol. Lack of …
Infliximab, a murine-human monoclonal antibody, is highly efficacious in the treatment of moderate-to-severe psoriasis, with better skin cle …
Drugs for psoriasis.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2019 Jun 17;61(1574):89-96. Med Lett Drugs Ther. 2019. PMID: 31381544 Review. No abstract available.
Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp.
McCormack PL. McCormack PL. Am J Clin Dermatol. 2011 Dec 1;12(6):421-4. doi: 10.2165/11207670-000000000-00000. Am J Clin Dermatol. 2011. PMID: 21967117 Review.
Calcipotriene/betamethasone dipropionate was generally well tolerated, with most adverse drug reactions being lesional or perilesional effects of mild or moderate severity. Calcipotriene/betamethasone dipropionate was often associated with fewer lesion
Calcipotriene/betamethasone dipropionate was generally well tolerated, with most adverse drug reactions being lesional or peri
Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration.
Rademaker M, Agnew K, Andrews M, Armour K, Baker C, Foley P, Frew J, Gebauer K, Gupta M, Kennedy D, Marshman G, Sullivan J. Rademaker M, et al. Australas J Dermatol. 2018 May;59(2):86-100. doi: 10.1111/ajd.12641. Epub 2017 May 23. Australas J Dermatol. 2018. PMID: 28543445 Review.
The topical and systemic therapies commonly used in psoriasis are each discussed separately, with regards to pregnancy exposure, breast-feeding and effects on male fertility and mutagenicity. The systemic therapies included are acitretin, adalimumab, apremilast, certolizum …
The topical and systemic therapies commonly used in psoriasis are each discussed separately, with regards to pregnancy exposure, breast-feed …
Topical calcipotriol/betamethasone dipropionate for psoriasis vulgaris: A systematic review.
Yan R, Jiang S, Wu Y, Gao XH, Chen HD. Yan R, et al. Indian J Dermatol Venereol Leprol. 2016 Mar-Apr;82(2):135-44. doi: 10.4103/0378-6323.175919. Indian J Dermatol Venereol Leprol. 2016. PMID: 26924402 Free article. Review.
However, the efficacy of this combination needs to be consolidated. We aimed to assess the effects and safety profile of calcipotriol/betamethasone dipropionate for the treatment of psoriasis vulgaris, using evidence based approach. ...The adverse events of …
However, the efficacy of this combination needs to be consolidated. We aimed to assess the effects and safety profile of calcipotr
Treatments for Cutaneous Lichen Planus: A Systematic Review and Meta-Analysis.
Atzmony L, Reiter O, Hodak E, Gdalevich M, Mimouni D. Atzmony L, et al. Am J Clin Dermatol. 2016 Feb;17(1):11-22. doi: 10.1007/s40257-015-0160-6. Am J Clin Dermatol. 2016. PMID: 26507510 Review.
The secondary outcomes were partial response, relapse, time to relapse, reduction of itch, the adverse event rate, and withdrawal due to adverse events. DATA SYNTHESIS: Sixteen studies met the inclusion criteria, of which 11 were randomized controlled trials. ...Bet …
The secondary outcomes were partial response, relapse, time to relapse, reduction of itch, the adverse event rate, and withdrawal due …
Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).
Leonardi C, Bagel J, Yamauchi P, Pariser D, Xu Z, Olesen M, Østerdal ML, Stein Gold L. Leonardi C, et al. J Drugs Dermatol. 2015 Dec;14(12):1468-77. J Drugs Dermatol. 2015. PMID: 26659941 Clinical Trial.
INTRODUCTION: An innovative aerosol foam formulation of calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) designed to improve treatment outcomes. ...SECONDARY OUTCOMES: modified (excluding head) psoriasis area and severity index (mPASI) and patient's a …
INTRODUCTION: An innovative aerosol foam formulation of calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) design …
377 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page